Antihypertensive drugs in blood donations in Serbia - Observational study

Z Budakov Obradović; S Lazarević; M Đanić; V Vasović; D Savić; G Smieško; M Mikov

doi:10.1016/j.transci.2023.103790

Antihypertensive drugs in blood donations in Serbia - Observational study

Transfus Apher Sci. 2023 Dec;62(6):103790. doi: 10.1016/j.transci.2023.103790. Epub 2023 Aug 21.

Authors

Z Budakov Obradović¹, S Lazarević², M Đanić³, V Vasović³, D Savić⁴, G Smieško⁵, M Mikov³

Affiliations

¹ Department of Internal Medicine, Blood Transfusion Unit, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
² Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia. Electronic address: slavica.lazarevic@mf.uns.ac.rs.
³ Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
⁴ Department of Surgery, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
⁵ Department of Microbiology, Parasitology and Immunology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.

PMID: 37640602
DOI: 10.1016/j.transci.2023.103790

Abstract

Introduction: Most of the blood banks worldwide do not defer donors for their medication, with the exception of the teratogenic and platelet aggregation-inhibiting drugs use. In Serbia, where around 245.000 units of blood are collected each year, it is not common practice to consider the medication of potential blood donors. Therefore, the aim of this study was to quantify the presence of antihypertensive drugs in blood samples collected from blood donors treated for hypertension and to raise the issue of the recipient risks posed by drug residues in blood products.

Methods: Serum samples were obtained from 450 volunteer blood donors collected during the year 2017 who reported the use of antihypertensive drugs. All blood donors were required to interrupt regular antihypertensive therapy for 24 h before blood donation and LCMS determination of antihypertensive drugs was performed.

Results: Beta blockers were detected in 81 out of 203 samples which tested positive for the presence of antihypertensive drugs. Concentrations above the limit of quantification were determined in 58% of samples positive on beta blockers, containing metoprolol and bisoprolol in amounts sufficient to produce a therapeutic effect in the recipient.

Conclusion: Therefore, the obtained results suggested that the safety of blood donation from individuals with treated hypertension should not be neglected. A solution for this problem might be the establishment of a standard LCMS screening procedure as a tool for testing the blood of donors taking drugs.

Keywords: Antihypertensive drugs; Blood recipients; Donor’s medication; Drug monitoring; Transfusion.

Publication types

Observational Study

MeSH terms

Antihypertensive Agents* / pharmacology
Antihypertensive Agents* / therapeutic use
Blood Donation
Blood Donors
Humans
Hypertension*
Serbia

Substances

Antihypertensive Agents